Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Laura J. Janke is active.

Publication


Featured researches published by Laura J. Janke.


Cell | 2014

RIPK1 Blocks Early Postnatal Lethality Mediated by Caspase-8 and RIPK3

Christopher P. Dillon; Ricardo Weinlich; Diego A. Rodriguez; James G. Cripps; Giovanni Quarato; Prajwal Gurung; Katherine Verbist; Taylor L. Brewer; Fabien Llambi; Yi-Nan Gong; Laura J. Janke; Michelle A. Kelliher; Thirumala-Devi Kanneganti; Douglas R. Green

Receptor-interacting protein kinase (RIPK)-1 is involved in RIPK3-dependent and -independent signaling pathways leading to cell death and/or inflammation. Genetic ablation of ripk1 causes postnatal lethality, which was not prevented by deletion of ripk3, caspase-8, or fadd. However, animals that lack RIPK1, RIPK3, and either caspase-8 or FADD survived weaning and matured normally. RIPK1 functions in vitro to limit caspase-8-dependent, TNFR-induced apoptosis, and animals lacking RIPK1, RIPK3, and TNFR1 survive to adulthood. The role of RIPK3 in promoting lethality in ripk1(-/-) mice suggests that RIPK3 activation is inhibited by RIPK1 postbirth. Whereas TNFR-induced RIPK3-dependent necroptosis requires RIPK1, cells lacking RIPK1 were sensitized to necroptosis triggered by poly I:C or interferons. Disruption of TLR (TRIF) or type I interferon (IFNAR) signaling delayed lethality in ripk1(-/-)tnfr1(-/-) mice. These results clarify the complex roles for RIPK1 in postnatal life and provide insights into the regulation of FADD-caspase-8 and RIPK3-MLKL signaling by RIPK1.


Nature | 2016

Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells

Jennifer Martinez; Larissa D. Cunha; Sunmin Park; Mao Yang; Qun Lu; Robert C. Orchard; Quan Zhen Li; Mei Yan; Laura J. Janke; Cliff Guy; Andreas Linkermann; Herbert W. Virgin; Douglas R. Green

Defects in clearance of dying cells have been proposed to underlie the pathogenesis of systemic lupus erythematosus (SLE). Mice lacking molecules associated with dying cell clearance develop SLE-like disease, and phagocytes from patients with SLE often display defective clearance and increased inflammatory cytokine production when exposed to dying cells in vitro. Previously, we and others described a form of noncanonical autophagy known as LC3-associated phagocytosis (LAP), in which phagosomes containing engulfed particles, including dying cells, recruit elements of the autophagy pathway to facilitate maturation of phagosomes and digestion of their contents. Genome-wide association studies have identified polymorphisms in the Atg5 (ref. 8) and possibly Atg7 (ref. 9) genes, involved in both canonical autophagy and LAP, as markers of a predisposition for SLE. Here we describe the consequences of defective LAP in vivo. Mice lacking any of several components of the LAP pathway show increased serum levels of inflammatory cytokines and autoantibodies, glomerular immune complex deposition, and evidence of kidney damage. When dying cells are injected into LAP-deficient mice, they are engulfed but not efficiently degraded and trigger acute elevation of pro-inflammatory cytokines but not anti-inflammatory interleukin (IL)-10. Repeated injection of dying cells into LAP-deficient, but not LAP-sufficient, mice accelerated the development of SLE-like disease, including increased serum levels of autoantibodies. By contrast, mice deficient in genes required for canonical autophagy but not LAP do not display defective dying cell clearance, inflammatory cytokine production, or SLE-like disease, and, like wild-type mice, produce IL-10 in response to dying cells. Therefore, defects in LAP, rather than canonical autophagy, can cause SLE-like phenomena, and may contribute to the pathogenesis of SLE.


Cell Reports | 2013

Protective Roles for Caspase-8 and cFLIP in Adult Homeostasis

Ricardo Weinlich; Andrew Oberst; Christopher P. Dillon; Laura J. Janke; John R. Lukens; Diego A. Rodriguez; Prajwal Gurung; Chandra Savage; Thirumala Kanneganti; Douglas R. Green

Caspase-8 or cellular FLICE-like inhibitor protein (cFLIP) deficiency leads to embryonic lethality in mice due to defects in endothelial tissues. Caspase-8(-/-) and receptor-interacting protein kinase-3 (RIPK3)(-/-), but not cFLIP(-/-) and RIPK3(-/-), double-knockout animals develop normally, indicating that caspase-8 antagonizes the lethal effects of RIPK3 during development. Here, we show that the acute deletion of caspase-8 in the gut of adult mice induces enterocyte death, disruption of tissue homeostasis, and inflammation, resulting in sepsis and mortality. Likewise, acute deletion of caspase-8 in a focal region of the skin induces local keratinocyte death, tissue disruption, and inflammation. Strikingly, RIPK3 ablation rescues both phenotypes. However, acute loss of cFLIP in the skin produces a similar phenotype that is not rescued by RIPK3 ablation. TNF neutralization protects from either acute loss of caspase-8 or cFLIP. These results demonstrate that caspase-8-mediated suppression of RIPK3-induced death is required not only during development but also for adult homeostasis. Furthermore, RIPK3-dependent inflammation is dispensable for the skin phenotype.


Blood | 2013

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia

Eric I. Zimmerman; David C. Turner; Jassada Buaboonnam; Shuiying Hu; Shelley Orwick; Michael S. Roberts; Laura J. Janke; Clinton F. Stewart; Hiroto Inaba; Sharyn D. Baker

FLT3 kinase internal tandem duplication (ITD) mutations are common in acute myeloid leukemia (AML) and are associated with poor clinical outcomes. Although initial responses to FLT3 tyrosine kinase inhibitors (TKIs) are observed in FLT3-ITD-positive patients, subsequent relapse often occurs upon acquisition of secondary FLT3 kinase domain (KD) mutations, primarily at residues D835 and F691. Using biochemical assays, we determined that crenolanib, a novel TKI, demonstrates type I properties and is active against FLT3 containing ITD and/or D835- or F691-activating mutations. Potent activity was observed in FLT3-ITD-positive AML cell lines. Crenolanib delayed the outgrowth of MV4-11 cells in a xenograft mouse model, whereas in combination with the type II TKI sorafenib, a significant decrease in leukemic burden (P < .001) and prolonged survival (P < .01) was observed compared with either type I or II TKI alone. Crenolanib was active against Ba/F3 cells harboring FLT3-ITD and secondary KD mutations and sorafenib-resistant MOLM-13 cells containing FLT3-ITD/D835Y both in vitro and in vivo. In addition, crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations. These preclinical data demonstrate that crenolanib is effective against FLT3-ITD containing secondary KD mutations, suggesting that crenolanib may be a useful therapeutic agent for TKI-naive and drug-resistant FLT3-ITD-positive AML.


Proceedings of the National Academy of Sciences of the United States of America | 2013

Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2

Jason A. Sprowl; Giuliano Ciarimboli; Cynthia S. Lancaster; Hugh Giovinazzo; Alice A. Gibson; Guoqing Du; Laura J. Janke; Guido Cavaletti; Anthony F. Shields; Alex Sparreboom

Oxaliplatin is an integral component of colorectal cancer therapy, but its clinical use is associated with a dose-limiting peripheral neurotoxicity. We found that the organic cation transporter 2 (OCT2) is expressed on dorsal root ganglia cells within the nervous system where oxaliplatin is known to accumulate. Cellular uptake of oxaliplatin was increased by 16- to 35-fold in cells overexpressing mouse Oct2 or human OCT2, and this process was associated with increased DNA platination and oxaliplatin-induced cytotoxicity. Furthermore, genetic or pharmacologic knockout of Oct2 protected mice from hypersensitivity to cold or mechanical-induced allodynia, which are established tests to assess acute oxaliplatin-induced neurotoxicity. These findings provide a rationale for the development of targeted approaches to mitigate this debilitating toxicity.


Cancer Cell | 2015

Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia

Michelle L. Churchman; Jonathan Low; Chunxu Qu; Elisabeth Paietta; Lawryn H. Kasper; Yunchao Chang; Debbie Payne-Turner; Mark J. Althoff; Guangchun Song; Shann Ching Chen; Jing Ma; Michael Rusch; Dan McGoldrick; Michael Edmonson; Pankaj Gupta; Yong Dong Wang; William Caufield; Burgess B. Freeman; Lie Li; John C. Panetta; Sharyn D. Baker; Yung-Li Yang; Kathryn G. Roberts; Kelly McCastlain; Ilaria Iacobucci; Jennifer L. Peters; Victoria E. Centonze; Faiyaz Notta; Stephanie M. Dobson; Sasan Zandi

Alterations of IKZF1, encoding the lymphoid transcription factor IKAROS, are a hallmark of high-risk acute lymphoblastic leukemia (ALL), however the role of IKZF1 alterations in ALL pathogenesis is poorly understood. Here, we show that in mouse models of BCR-ABL1 leukemia, Ikzf1 and Arf alterations synergistically promote the development of an aggressive lymphoid leukemia. Ikzf1 alterations result in acquisition of stem cell-like features, including self-renewal and increased bone marrow stromal adhesion. Retinoid receptor agonists reversed this phenotype, partly by inducing expression of IKZF1, resulting in abrogation of adhesion and self-renewal, cell cycle arrest, and attenuation of proliferation without direct cytotoxicity. Retinoids potentiated the activity of dasatinib in mouse and human BCR-ABL1 ALL, providing an additional therapeutic option in IKZF1-mutated ALL.


Journal of Experimental Medicine | 2014

Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential

Louise M. Treanor; Sheng Zhou; Laura J. Janke; Michelle L. Churchman; Zhijun Ma; Taihe Lu; Shann-Ching Chen; Charles G. Mullighan; Brian P. Sorrentino

Two interleukin-7 receptor mutants identified in human early T cell precursor leukemia are sufficient to induce disease in mice when expressed in primitive, Arf-null thymocytes.


Blood | 2015

Pax5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia

Jinjun Dang; Lei Wei; Jeroen de Ridder; Xiaoping Su; Alistair G. Rust; Kathryn G. Roberts; Debbie Payne-Turner; Jinjun Cheng; Jing Ma; Chunxu Qu; Gang Wu; Guangchun Song; Robert Huether; Brenda A. Schulman; Laura J. Janke; Jinghui Zhang; James R. Downing; Louise van der Weyden; David J. Adams; Charles G. Mullighan

Alterations of genes encoding transcriptional regulators of lymphoid development are a hallmark of B-progenitor acute lymphoblastic leukemia (B-ALL) and most commonly involve PAX5, encoding the DNA-binding transcription factor paired-box 5. The majority of PAX5 alterations in ALL are heterozygous, and key PAX5 target genes are expressed in leukemic cells, suggesting that PAX5 may be a haploinsufficient tumor suppressor. To examine the role of PAX5 alterations in leukemogenesis, we performed mutagenesis screens of mice heterozygous for a loss-of-function Pax5 allele. Both chemical and retroviral mutagenesis resulted in a significantly increased penetrance and reduced latency of leukemia, with a shift to B-lymphoid lineage. Genomic profiling identified a high frequency of secondary genomic mutations, deletions, and retroviral insertions targeting B-lymphoid development, including Pax5, and additional genes and pathways mutated in ALL, including tumor suppressors, Ras, and Janus kinase-signal transducer and activator of transcription signaling. These results show that in contrast to simple Pax5 haploinsufficiency, multiple sequential alterations targeting lymphoid development are central to leukemogenesis and contribute to the arrest in lymphoid maturation characteristic of ALL. This cross-species analysis also validates the importance of concomitant alterations of multiple cellular growth, signaling, and tumor suppression pathways in the pathogenesis of B-ALL.


Immunity | 2016

Apoptosis-Inducing-Factor-Dependent Mitochondrial Function Is Required for T Cell but Not B Cell Function

Christopher P. Dillon; Oliver E. Sturm; Katherine Verbist; Taylor L. Brewer; Giovanni Quarato; Scott A. Brown; Sharon Frase; Laura J. Janke; S. Scott Perry; Paul G. Thomas; Douglas R. Green

The role of apoptosis inducing factor (AIF) in promoting cell death versus survival remains controversial. We report that the loss of AIF in fibroblasts led to mitochondrial electron transport chain defects and loss of proliferation that could be restored by ectopic expression of the yeast NADH dehydrogenase Ndi1. Aif-deficiency in T cells led to decreased peripheral T cell numbers and defective homeostatic proliferation, but thymic T cell development was unaffected. In contrast, Aif-deficient B cells developed and functioned normally. The difference in the dependency of T cells versus B cells on AIF for function and survival correlated with their metabolic requirements. Ectopic Ndi1 expression rescued homeostatic proliferation of Aif-deficient T cells. Despite its reported roles in cell death, fibroblasts, thymocytes and B cells lacking AIF underwent normal death. These studies suggest that the primary role of AIF relates to complex I function, with differential effects on T and B cells.


Journal of Experimental Medicine | 2013

Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation

Wai-Hang Leung; Queenie P. Vong; Wenwei Lin; Laura J. Janke; Taosheng Chen; Wing Leung

The diuretic drug spironolactone up-regulates NKG2D ligand expression in colon cancer cells via activation of the ATM–Chk2–mediated checkpoint pathway to enhance the antitumor function of NK cells.

Collaboration


Dive into the Laura J. Janke's collaboration.

Top Co-Authors

Avatar

Charles G. Mullighan

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Mary V. Relling

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Lie Li

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Debbie Payne-Turner

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Laura B. Ramsey

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

William E. Evans

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brian P. Sorrentino

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Douglas R. Green

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Gerard Grosveld

St. Jude Children's Research Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge